Author:
Tang Grace H.,Acuna Sergio A.,Sevick Laura,Yan Andrew T.,Brezden-Masley Christine
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference27 articles.
1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92. doi: 10.1056/NEJM200103153441101 .
2. Mariani G, Fasolo A, De Benedictis E, Gianni L. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol. 2009;6:93–104. doi: 10.1038/ncponc1298 .
3. Sandoo A, Kitas GD, Carmichael AR. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer. Anticancer Res. 2014;34:1147–51.
4. Sendur MAN, Aksoy S, Altundag K. Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin. 2013;29:1015–24. doi: 10.1185/03007995.2013.807232 .
5. Albanell J, Ciruelos EM, Lluch A, Muñoz M, Rodríguez CA. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev. 2014;40:41–7. doi: 10.1016/j.ctrv.2013.04.002 .
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献